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Abstract
In the presence of new surgical techniques, the treatment of congenital valvular
aortic stenosis is under debate. We reviewed the results and late outcomes
of all 93 patients aged 1  day to 18  years, treated with balloon valvuloplasty
(BAV) as first-line therapy for congenital aortic valve stenosis in our center from
January 1991 to May 2012. Mean age at procedure time was 2.4  years; 37
patients underwent BAV at age ≤30 days (neonates), 29 patients at age ≥1 month
and <1  year (infants), and 27 patients were older than 1  year (children). The
invasive BAV peak-to-peak aortic valve gradient (mean 59  ±  22  mmHg) was
immediately reduced (mean 24 ± 12 mmHg). The observed diminution of gradient
was similar for each age group. Four patients had significant post-BAV AI. Mean
follow-up after BAV was 11.4 ± 7 years. The last echo peak aortic gradient was
37 ± 18 mmHg and mean gradient was 23 ± 10 mmHg, and two patients had
significant AI. Actuarial survival for t...
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Abstract In the presence of new surgical techniques, the
treatment of congenital valvular aortic stenosis is under
debate. We reviewed the results and late outcomes of all 93
patients aged 1 day to 18 years, treated with balloon
valvuloplasty (BAV) as first-line therapy for congenital
aortic valve stenosis in our center from January 1991 to May
2012. Mean age at procedure time was 2.4 years; 37 patients
underwent BAV at age B30 days (neonates), 29 patients at
age C1 month and \1 year (infants), and 27 patients were
older than 1 year (children). The invasive BAV peak-to-
peak aortic valve gradient (mean 59 ± 22 mmHg) was
immediately reduced (mean 24 ± 12 mmHg). The observed
diminution of gradient was similar for each age group. Four
patients had significant post-BAV AI. Mean follow-up after
BAV was 11.4 ± 7 years. The last echo peak aortic gradi-
ent was 37 ± 18 mmHg and mean gradient was 23 ±
10 mmHg, and two patients had significant AI. Actuarial
survival for the whole cohort was 88.2 and 72.9 % for the
neonates. All infants, except one, and all children survived.
Sixty-six percent of patients were free from surgery, and
58 % were free from any reintervention, with no difference
according to age. Freedom from surgery after BAV at 5, 10,
and 20 years, respectively, was 82, 72, and 66 %. Our study
confirms that BAV as primary treatment for congenital AS is
an efficient and low-risk procedure in infants and children.
In neonates, the prognosis is more severe and clearly related
to ‘‘borderline LV.’’
Keywords Congenital valvular aortic stenosis  Balloon
valvuloplasty  Outcome  Shone’s syndrome
Introduction
Congenital valvular aortic stenosis (AS) is relatively
common (1.1–4.3 per 10,000 live births) [3, 8]. Since
30 years, balloon aortic valvuloplasty (BAV) is the first-
line treatment in most centers worldwide [6, 9]. There
is still debate, however, concerning what is the most
appropriate treatment, especially in the context of new
surgical techniques such as aortic valve reconstruction or
the Ross procedure. We reviewed the results of all the
patients treated with BAV as first-line therapy in our
center, and we analyzed the results and late outcomes of
the procedure.
Materials and Methods
We reviewed the medical records of all patients aged 1 day
to 18 years, treated with BAV from January 1991 to May
2012 in the Cliniques Universitaires Saint Luc, UCL,
Brussels. Age, weight, gender, echocardiographic and he-
modynamic data, and need for re-intervention, and/or sur-
gery were collected.
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Transthoracic echocardiography (TTE) was used to
evaluate the anatomy of the aortic valve, with Doppler-
derived pressure gradients and insufficiency degree asses-
sed before and after the procedure. Left ventricular short-
ening fraction (LVSF) and left ventricular end-diastolic
diameter (LVDD) were collected. Peak and mean aortic
valve gradients were measured using the modified
Bernoulli equation. AS was considered significant if the
peak gradient exceeded 70 mmHg, without LV dysfunc-
tion. Aortic insufficiency (AI), detected by means of color
Doppler, was classified from 0 to 4, with grades 3–4 or 4
considered significant AI.
Percutaneous BAV was performed under general anes-
thesia usually via retrograde femoral artery access. Peak-
to-peak gradient through the aortic valve, presence of AI,
and annulus size were all assessed before and after the
procedure. Balloon sizes ranged from 4 to 25 mm, never
exceeding a balloon diameter to aortic annulus ratio of 0.9.
Patients with sub- or supra-valvular aortic stenosis, or
those exhibiting hypoplastic left heart syndrome (HLHS),
were not included in the study. In addition, those who had
undergone surgical aortic valvuloplasty as an initial treat-
ment were excluded from analysis.
SPSS statistical software was used for data analysis.
Categorical variables were reported as absolute numbers
and percentages. Continuous variables were expressed as
either mean ± standard deviation (SD) or median values
and ranges. For all tests, a p value \0.05 was considered
statistically significant. Actuarial survival and freedom
from reintervention were calculated using the Kaplan–
Meier method.
The study was conducted in accordance with the Belgian
regulatory requirements. Due to its retrospective study
design, neither IRB approval nor patient written informed
consent was required.
Results
From January 1991 to May 2012, 93 patients with con-
genital AS were referred to our center to undergo primary
BAV. Figure 1a depicts the distribution and frequency over
time. A description of the population and results can be
found in Table 1 and Fig. 1b. The mean age at procedure
time was 2.4 years, with 37 patients undergoing BAV aged
B30 days (neonates), 29 aged between 1 month and 1 year
(infants), and 27 aged over 1 year (children). The popula-
tion was 18 % female and 82 % male. Isolated bicuspid
aortic valve was diagnosed in 58 % of the cohort, with
16 % exhibiting Shone’s syndrome. After reviewing pa-
tient data and evolution, nine patients who had been se-
lected for BAV on account of an adequately sized left
ventricle were diagnosed as having multiple small left
ventricular structures, such as the mitral or aortic valve and
the aortic arch.
Prior to BAV, the Doppler-derived peak and mean aortic
valve gradients were 71 ± 18 and 44 ± 12 mmHg, re-
spectively. The mean LVSF was 42 ± 11 %, with LV
dysfunction (LVSF \ 30 %) reported in only three pa-
tients, all neonates.
During catheterization, the pre-BAV peak-to-peak aortic
valve gradient, measured invasively, was 59 ± 22 mmHg.
The post-BAV peak-to-peak gradient was immediately
reduced to 24 ± 12 mmHg. The observed decrease in
gradient was similar in all age groups. Only one patient
(neonate) exhibited a post-BAV peak-to-peak gradient
exceeding 50 mmHg, which was considered a failure. Yet
a spontaneous decrease in gradient was revealed on TTE
during follow-up, decreasing to 15 mmHg after 12.3 years,
despite no other procedure having been performed. An-
giographic nonsignificant AI (grade 1 or 2) was present in
eight patients before the procedure and in 37 patients after
the procedure, considered significant in four patients (grade
3 or 4).
Echocardiographic reports were available for follow-up
in 88 patients (94.6 %), with five lost to late follow-up. At
the last echo, the peak aortic gradient was 37 ± 18 mmHg
and mean gradient was 23 ± 10 mmHg, with a higher
residual gradient observed in the children group
(42 ± 18 mmHg). AI was reported in 52 patients (59 %),
with only two cases considered significant (one neonate
and one infant).
Mean follow-up duration after BAV was 11.4 ± 7 years,
with a maximum of 21.7 years. A total of 48 patients (51 %)
were followed up for over 10 years. The Kaplan–Meier
method showed an actuarial survival for the whole cohort of
88 % at last follow-up (Fig. 2a). Only 72.9 % of the neo-
nates were still alive, whereas all the children survived and
all the infants, except one, who died from surgical compli-
cations (Fig. 2b).
Out of the entire patient population, 66 % were free
from surgery at last follow-up, with no significant differ-
ence observed according to age (Table 1), and over half
(58 %) were free from any reintervention.
A second intervention (additional BAV or surgery) was
performed in 35 patients (37 %) after a mean time of
3.4 years. The results are presented in Table 2. A second
intervention was significantly more common in the chil-
dren, yet took place earlier in the neonate group. No dif-
ferences were observed in the reintervention type among
the three groups. A second BAV was performed in six
children (22 %) after a mean time of 5.7 years, in six in-
fants (20.7 %) after a mean time of 4.7 years, and in six
neonates (16 %) after a mean time of 0.6 years. Surgery
was performed as a second intervention in 17 patients
(18.2 %): six children (22 %) after a mean time of 6 years,
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four infants (13.8 %) after a mean time of 2.8 years, and
seven neonates (18.9 %) after a mean time of 1.1 years.
A Ross procedure was performed on 12 patients, a surgical
aortic valvuloplasty on two, and sub-aortic membrane re-
section on three. Within this patient group, one 15-year-old
patient required LV assistance and a heart transplant
following the Ross procedure, performed due to pre-
dominant aortic stenosis. This patient exhibited good final
evolution.
Repeat BAV procedures (C3 percutaneous interven-
tions) were conducted in five patients (5.4 %), comprising
two neonates, two infants, and one child. For three of these
Fig. 1 a Congenital AS distribution and frequency in Cliniques Universitaires Saint-Luc over study period, b flowchart of patient evolution
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patients (one neonate and two infants), surgery was even-
tually performed.
Surgery was performed as third or fourth intervention in
12 patients (12.9 %), consisting of four Ross procedures (in
two neonates, one infant, and one child), six aortic valvu-
loplasty (three infants and three children), one univen-
tricular palliation (in one neonate, who died during
surgery), and one heart transplantation (in the previously
mentioned 15-year-old patient with severe LV dysfunction
following the Ross procedure).
The indications for reinterventions in the 24 patients
operated on the aortic valve (16 Ross, eight aortic valve
repairs) were aortic stenosis in ten patients, insufficiency in
seven patients, and mixed stenosis and regurgitation in
seven patients, with aortic valve surgery performed mainly
to treat significant AI in 14 of those 24 patients (Fig. 1b).
Patient deaths (Table 3) concerned 10 neonates who had
undergone BAV at under 30 days of age, and one infant
who underwent BAV at 41 days old and died from post-
operative complications (Patient 10). Of the 10 neonates
who died, two (20 %) had presented with LV dysfunction
prior to BAV and eight either exhibited Shone’s syndrome
or were diagnosed as having multiple small or abnormal
left heart structures. Seven patients died within the
2 months following BAV, and only two patients died after
1 year of age.
In four patients, death was related to catheterization
complications: Two patients developed significant AI
following BAV (one infant [Patient 3] died 7 days after a
rescue Ross procedure and the other [Patient 5] 2 weeks
following BAV), one patient died from a mitral tear re-
sulting in severe regurgitation during a second BAV pro-
cedure (Patient 8), and the fourth died from cerebral
hemorrhage during streptokinase treatment for femoral
artery thrombosis (Patient 9).
Three patients died from surgical complications, con-
sisting of aortic dissection during coarctation repair (Pa-
tient 4), air embolism (Patient 10), and stroke during
extracorporeal life support following a heart transplant
(Patient 11).
In eight neonate patients, death was at least partially
related to inadequate LV or left heart structure dimensions
(Table 3). One of the eight neonates died following a
rescue Norwood procedure (Patient 7), one from LV fi-
broelastosis revealed during the Ross procedure (Patient 6),
and one from persistent LV diastolic dysfunction 6.8 years
after a Ross procedure (Patient 11 who died from cerebral
hemorrhage following a heart transplant).
Discussion
Our study presents the results and outcomes from a 20-year
experience with BAV as an initial treatment for congenital
AS in a pediatric population. BAV is an efficient proce-
dure, demonstrated by the significant decrease in aortic
Table 1 Population data and BAV results in the whole cohort by age group
Total Neonates Infants Children p
Patients (n) 93 37 29 27
Age at BAV 2.4 years 6.7 days 2.7 m ± 1.8 2.4 years
Gender (m/f) 76/17 32/5 22/7 22/5
Weight (kg) 10 ± 1.1 3.2 ± 0.5 4.7 ± 1.4 31.7 ± 17
Pre-BAV TTE
LVSF (%) 42 ± 11 40 ± 8 46 ± 10 46 ± 9
LVDD (mm) 23 ± 0.8 18.8 ± 5 22.7 ± 4 38 ± 10
Balloon aortic valvuloplasty
Pre-BAV LV–AO gradient (mmHg) 59 ± 22 65 ± 24 52.3 ± 15.4 57 ± 21
Post-BAV LV–AO gradient (mmHg) 24 ± 12 25 ± 12 21 ± 12 28.6 ± 10
Aortic annular diameter (mm) 9.8 ± 4.4 6.7 ± 1.1 8.9 ± 1.5 17 ± 3.5
Pre-BAV AI (1–4/4) 8 3 1 4
Post-BAV significant AI (C3/4) 4 2 1 1
Mean follow-up (years) 11.4 (0.014–27.1) 7.4 (0.014––18.6) 10 (0.14–21.5) 18.2 (3.7–27.1)
TTE peak LV–AO gradient (mmHg) 37 ± 17.7 37.6 ± 17.8 31.6 ± 15 42.5 ± 18.7
TTE mean LV–AO gradient (mmHg) 23 ± 9.7 21.5 ± 8.3 20.7 ± 10.5 28 ± 9.5
Significant AI (C3/4) 2 1 1 0
Overall survival 83 (89.2 %) 27 (72.9 %) 28 (97 %) 27 (100 %) p \ 0.01
Free from surgery 62 (66.7 %) 22 (72.9 %) 22(75.8 %) 18 (66.7 %)
Free from reintervention 54 (58 %) 20 (54 %) 19 (65.5 %) 15 (55.5 %)
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gradient we observed immediately after the procedure and
at late follow-up in all groups. Our survival analysis, with a
mean follow-up of 11.4 ± 7 years, revealed that 88 % of
patients were alive at 20 years of age, with two-thirds of
the cohort free from surgery and over half free from any
reintervention. These findings are in line with the literature
[1, 6, 9]. Nevertheless, a second intervention (either sur-
gery or BAV—36 % in our series) appeared unavoidable in
a third of patients in the long term [7, 12, 13].
The mortality rate was 11.8 % for the whole cohort and
27 % for the neonate subgroup. The 73 % survival reported
in neonates with critical aortic stenosis in our series was
similar to the 72 % survival at 5 years reported in the
Congenital Heart Surgeons’ Society multicentric study
[10]. In our series, all deaths involved neonates, except
one. The causes of death were multifactorial: In four cases,
death was considered secondary to BAV complications,
and in eight cases (8/11—72 %), patients were finally di-
agnosed with a ‘‘borderline LV’’ with abnormal left heart
structures or non-compliant LV, clearly associated with an
increased risk of poor results and death [14]. When neo-
nates are diagnosed with a ‘‘borderline LV,’’ predicting
which is suitable for biventricular repair remains a sub-
stantial challenge [2, 5, 11] and the presence of endocardial
fibroelastosis with LV diastolic dysfunction appears to be a
more significant risk factor than LV volume or dimensions
[14]. LV systolic dysfunction preceding BAV also tended
to be associated with poor survival. Although as it con-
cerned only three patients in our study, this assessment
should be interpreted with caution.
Another relevant observation was the fact that 66.7 % of
the whole population was free from surgery at the last
follow-up. The freedom from surgery after BAV of 82, 72,
and 66 % at 5, 10, and 20 years of follow-up, respectively,
is even more appealing for physicians in charge of young
children (Fig. 3).
This result should be compared to the 50 % freedom
from surgical reintervention and valve replacement at
10 years that was recently reported in a pediatric popula-
tion following aortic valve repair performed by the most
skilled surgeons [4]. The graphs published in this actual
surgical study demonstrated 70 % freedom of reinterven-
tion at 10 years after aortic valve repair with no cusp ex-
tension, yet only 30 % freedom of reintervention when
cusp extension was performed. For neonates with critical
aortic stenosis, the prospective non-randomized study by
Fig. 2 a Patient survival at last follow-up was 89.2 %, b patient
survival by age at first catheterization. Except one infant who died at
1 year of age from air embolism during surgical aortic valvuloplasty
(patient 10, Table 3), all infant and children were alive (98 % survival
rate); 72.9 % of the neonates were alive
Table 2 Second intervention Total Neonates Infants Children p
Secondnd intervention 35 (37.3 %) 13 (35.1 %) 10 (34.5 %) 12 (44.4 %) p \ 0.05
Mean time after first BAV (years) 3.4 0.7 4.4 5.6 p \ 0.05
Cath 18 (19.3 %) 6 (16 %) 6 (20.7 %) 6 (22 %)
Mean time after first BAV (years) 3.7 0.6 4.7 5.7 p \ 0.05
Surgery 17 (18.2 %) 7 (18.9 %) 4 (13.8 %) 6 (22 %)
Mean time after first BAV (years) 3.3 1.1 2.8 6
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the Congenital Heart Surgeons’ Society reported similar
survival and outcomes following valvotomy, performed
surgically or by transcatheter balloon dilatation [10]. His-
torical series demonstrate, as does our study, that balloon
valvuloplasty achieves at least similar results to surgery in
terms of survival and reoperation rates. For the pediatric
population, even with the advent of new surgical techniques,
aortic valve repair or replacement must be reserved for pa-
tients who failed to benefit from balloon valvuloplasty.
Ultimately, most patients will require a reintervention by
surgery or balloon dilatation (Fig. 4). Balloon valvuloplasty is
easy to repeat if necessary, as it was performed twice in 18
patients and three times in five. This procedure did not preclude
a successful aortic surgical valvuloplasty in eight children.
Study Limitations
This was a retrospective, monocenter, and non-com-
parative study. Our cohort was not very large compared
with other studies reported in the literature, and our results
must thus be interpreted carefully. Furthermore, the data
were collected over a long time period, and the
Table 3 Data of the patients who died
Patient Age at first
BAV (days)
Age at
death
(days)
Date
of
birth
Causes of death Death related to
abnormal LV
Death related to
cath complication
Postoperative death
1 2 6 1991 Severe mitral regurgitation,
Shone syndrome
LV
2 2 8 2012 Severe LV dysfunction, Shone
syndrome
LV
3 3 10 1992 Cath complication, AO regurg,
postop death (Ross—day 1)
AO regurgitation Ross procedure
4 2 13 1993 Shone syndrome, postop death
(COA repair—day 1)
LV COA repair under
bypass
5 3 18 1999 Cath complication, severe AO
regurg
LV AO regurgitation
6 1 16 2007 Fibroelastosis, postop death
(Ross-Kono, day 1)
LV Ross procedure
7 1 36 2010 Fibroelastosis, postop death
(Norwood, day 1)
LV Norwood procedure
8 25 96 1995 Cath complication (second
procedure), mitral regurg
Mitral regurgitation Mitral plasty (6 days
postcath)
9 5 81 1999 Cath complication (second
procedure), cerebral
hemorrhage
LV Streptokinase for
femoral
thrombosis
10 41 392 1994 Postop death (valvuloplasty,
day 1)
AO valvuloplasty air
embolism
11 4 2564 2001 Fibroelastosis, postop death
(transplant, ECMO, day 2)
LV Transplant, ECMO,
cerebral
hemorrhage
Fig. 3 Freedom from surgery after BAV at 5, 10, and 20 years of
follow-up were, respectively, 82, 72, and 66 %
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interventions were performed by different physicians, us-
ing different materials and techniques, which could have
impacted the results [15]. It is important to note that during
the study period, BAV was performed by six different
cardiologists. While our results reflect a realistic picture of
general BAV outcomes, this could have reinforced differ-
ences in patient selection and treatment strategy, partially
explaining some of the neonatal deaths.
Echocardiographic data were collected by reviewing
echo reports, although these were not standardized and had
been performed by multiple cardiologists. Another limita-
tion was the use of LV shortening fraction to assess LV
systolic function, which does not precisely reflect my-
ocardial contractility [9], as well as the use of LV end-
diastolic dimension to assess LV dimensions. Our center
uses BAV as standard management for congenital AS, and
no primary surgical aortic valvuloplasty was performed
during this time period. For this reason, it was not possible
to compare the outcomes of primary BAV with those of
primary surgical aortic valvuloplasty.
Conclusion
This study confirmed that BAV is an efficient and low-risk
primary treatment for congenital AS in infants and chil-
dren, resulting in a 98 % survival and over half the
population remaining free from any reintervention after a
mean period of 11.4 ± 7 years. In neonates with critical
aortic stenosis selected for biventricular repair, the 72.9 %
survival at 10 years in our series was in line with the 72 %
survival at 5 years reported by BW. Mc Crindle in the
Congenital Heart Surgeons’ Society prospective non-ran-
domized study [10]. In neonates, the prognosis appears
more severe, clearly related to ‘‘borderline LV’’ and the
challenge of recognizing which is suitable or not for a
biventricular management strategy [14].
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